Published in Pharmacogenet Genomics on July 01, 2013
Psychostimulant addiction treatment. Neuropharmacology (2014) 0.91
A review of pharmacogenetic studies of substance-related disorders. Drug Alcohol Depend (2015) 0.79
Declinol, a Complex Containing Kudzu, Bitter Herbs (Gentian, Tangerine Peel) and Bupleurum, Significantly Reduced Alcohol Use Disorders Identification Test (AUDIT) Scores in Moderate to Heavy Drinkers: A Pilot Study. J Addict Res Ther (2013) 0.76
Addiction pharmacogenetics: a systematic review of the genetic variation of the dopaminergic system. Psychiatr Genet (2015) 0.76
Integrative Bayesian analysis of neuroimaging-genetic data with application to cocaine dependence. Neuroimage (2015) 0.75
The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry (1998) 65.11
The Fifth Edition of the Addiction Severity Index. J Subst Abuse Treat (1992) 29.45
Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation. JAMA (2000) 14.17
The dopamine D2 receptor locus as a modifying gene in neuropsychiatric disorders. JAMA (1991) 5.84
The genetics of addictions: uncovering the genes. Nat Rev Genet (2005) 5.05
Allelic association of human dopamine D2 receptor gene in alcoholism. JAMA (1990) 5.04
Addiction is a brain disease, and it matters. Science (1997) 4.68
Efficacy of disulfiram and cognitive behavior therapy in cocaine-dependent outpatients: a randomized placebo-controlled trial. Arch Gen Psychiatry (2004) 3.72
PET imaging of dopamine D2 receptors during chronic cocaine self-administration in monkeys. Nat Neurosci (2006) 3.13
Polymorphisms in the dopamine D2 receptor gene and their relationships to striatal dopamine receptor density of healthy volunteers. Mol Psychiatry (1999) 2.90
Identification and characterization of ANKK1: a novel kinase gene closely linked to DRD2 on chromosome band 11q23.1. Hum Mutat (2004) 2.89
The A1 allele of the human D2 dopamine receptor gene predicts low D2 receptor availability in healthy volunteers. Mol Psychiatry (1998) 2.88
Treatment of cocaine and alcohol dependence with psychotherapy and disulfiram. Addiction (1998) 2.88
Polymorphisms in human dopamine D2 receptor gene affect gene expression, splicing, and neuronal activity during working memory. Proc Natl Acad Sci U S A (2007) 2.62
Allelic association of the D2 dopamine receptor gene with receptor-binding characteristics in alcoholism. Arch Gen Psychiatry (1991) 2.30
D2 dopamine receptor gene (DRD2) Taq1 A polymorphism: reduced dopamine D2 receptor binding in the human striatum associated with the A1 allele. Pharmacogenetics (1997) 2.28
The genetic basis for smoking behavior: a systematic review and meta-analysis. Nicotine Tob Res (2004) 2.28
A national 5-year follow-up of treatment outcomes for cocaine dependence. Arch Gen Psychiatry (2002) 1.99
How important is treatment? One-year outcomes of treated and untreated alcohol-dependent individuals. Addiction (2003) 1.97
Haplotype spanning TTC12 and ANKK1, flanked by the DRD2 and NCAM1 loci, is strongly associated to nicotine dependence in two distinct American populations. Hum Mol Genet (2006) 1.94
Association of seven polymorphisms of the D2 dopamine receptor gene with brain receptor-binding characteristics. Neurochem Res (2003) 1.88
Manual-guided psychosocial treatment. A new virtual requirement for pharmacotherapy trials? Arch Gen Psychiatry (1997) 1.74
Disulfiram treatment for cocaine dependence in methadone-maintained opioid addicts. Addiction (2000) 1.66
Predicting cocaine use among methadone patients: analysis of findings from a national study. Hosp Community Psychiatry (1992) 1.61
Disulfiram versus placebo for cocaine dependence in buprenorphine-maintained subjects: a preliminary trial. Biol Psychiatry (2000) 1.55
Association of haplotypic variants in DRD2, ANKK1, TTC12 and NCAM1 to alcohol dependence in independent case control and family samples. Hum Mol Genet (2007) 1.55
Prominence of the dopamine D2 short isoform in dopaminergic pathways. Proc Natl Acad Sci U S A (1998) 1.52
Family-based association analyses of alcohol dependence phenotypes across DRD2 and neighboring gene ANKK1. Alcohol Clin Exp Res (2007) 1.47
Heroin use during methadone maintenance treatment: the importance of methadone dose and cocaine use. Am J Public Health (1995) 1.40
D2 dopamine receptor gene TaqI A1 and B1 restriction fragment length polymorphisms: enhanced frequencies in psychostimulant-preferring polysubstance abusers. Biol Psychiatry (1996) 1.38
Dopamine beta-hydroxylase knockout mice have alterations in dopamine signaling and are hypersensitive to cocaine. Neuropsychopharmacology (2005) 1.35
Intronic polymorphisms affecting alternative splicing of human dopamine D2 receptor are associated with cocaine abuse. Neuropsychopharmacology (2010) 1.29
Pharmacogenetic randomized trial for cocaine abuse: disulfiram and dopamine β-hydroxylase. Biol Psychiatry (2012) 1.27
Allelic association of the D2 dopamine receptor gene with cocaine dependence. Drug Alcohol Depend (1993) 1.27
Cocaine use and HIV risk behavior in methadone maintenance patients. Drug Alcohol Depend (1995) 1.27
Haplotypic variants in DRD2, ANKK1, TTC12, and NCAM1 are associated with comorbid alcohol and drug dependence. Alcohol Clin Exp Res (2008) 1.22
Emerging pharmacological strategies in the fight against cocaine addiction. Expert Opin Emerg Drugs (2006) 1.20
Effects of dopamine beta-hydroxylase genotype and disulfiram inhibition on catecholamine homeostasis in mice. Psychopharmacology (Berl) (2005) 1.20
Disulfiram and diethyldithiocarbamate intoxication affects the storage and release of striatal dopamine. Toxicol Appl Pharmacol (1996) 1.17
HIV infection and cocaine use in methadone maintained and untreated intravenous drug users. Drug Alcohol Depend (1994) 1.15
The D(2) dopamine receptor A(1) allele and opioid dependence: association with heroin use and response to methadone treatment. Am J Med Genet (2000) 1.10
A study of the dopamine D2 receptor gene in pathological gambling. Pharmacogenetics (1996) 1.10
Family-based association testing strongly implicates DRD2 as a risk gene for schizophrenia in Han Chinese from Taiwan. Mol Psychiatry (2008) 1.09
Association of the A1 allele of the D2 dopamine receptor gene with severe alcoholism. Alcohol (1992) 1.05
Single nucleotide polymorphisms in ANKK1 and the dopamine D2 receptor gene affect cognitive outcome shortly after traumatic brain injury: a replication and extension study. Brain Inj (2008) 1.01
Antecedents and consequences of cocaine abuse among opioid addicts. A 2.5-year follow-up. J Nerv Ment Dis (1988) 1.00
D2 dopamine receptor (DRD2) gene Taq1A polymorphism and the eating-related psychological traits in eating disorders (anorexia nervosa and bulimia) and obesity. Eat Weight Disord (2007) 0.99
Mechanisms of cellular adaptive sensitivity changes: applications to opioid tolerance and dependence. Pharmacol Rev (1989) 0.98
Methadone-related deaths in Palm Beach County. J Forensic Sci (2004) 0.97
Antidepressants for cocaine dependence. Cochrane Database Syst Rev (2003) 0.97
Changes in HIV risk behaviors among cocaine-using methadone patients. J Addict Dis (1998) 0.96
The long-term outcomes of drug use by methadone maintenance patients. J Behav Health Serv Res (2003) 0.94
The ANKK1 gene associated with addictions is expressed in astroglial cells and upregulated by apomorphine. Biol Psychiatry (2010) 0.92
Heavy nicotine and alcohol use in alcohol dependence is associated with D2 dopamine receptor (DRD2) polymorphism. Addict Behav (2007) 0.91
Treating cocaine-using methadone patients: predictors of outcomes in a psychosocial clinical trial. Subst Use Misuse (2002) 0.89
Modifying the role of serotonergic 5-HTTLPR and TPH2 variants on disulfiram treatment of cocaine addiction: a preliminary study. Genes Brain Behav (2012) 0.86
Carbamazepine for cocaine dependence. Cochrane Database Syst Rev (2002) 0.86
A DRD2 and ANKK1 haplotype is associated with nicotine dependence. Psychiatry Res (2012) 0.85
Allelic and genotypic associations of DRD2 TaqI A polymorphism with heroin dependence in Spanish subjects: a case control study. Behav Brain Funct (2007) 0.85
Influence of ANKK1 and DRD2 polymorphisms in response to haloperidol. Eur Arch Psychiatry Clin Neurosci (2012) 0.82
Polymorphisms of the D2 dopamine receptor gene and alcoholism and other substance use disorders. Alcohol Alcohol Suppl (1994) 0.82
Association and excess of transmission of a DRD2 haplotype in a sample of French schizophrenic patients. Schizophr Res (2001) 0.81
Psychotherapeutic treatment of cocaine abuse: models for its evaluation alone and in combination with pharmacotherapy. NIDA Res Monogr (1993) 0.81
Association between the dopamine D2 receptor TaqI A2 allele and low activity COMT allele with obsessive-compulsive disorder in males. Eur Neuropsychopharmacol (2006) 0.81
Factors associated with client-reported HIV infection among clients entering methadone treatment. AIDS Educ Prev (1997) 0.81
The effect of increased cocaine use on drug treatment. Addict Behav (1987) 0.81
Analysis of the linkage of the Taq1A and Taq1B loci of the dopamine D2 receptor gene with schizophrenia in patients and their siblings. Neurosci Behav Physiol (2003) 0.79
Systematic review: opioid treatment for chronic back pain: prevalence, efficacy, and association with addiction. Ann Intern Med (2007) 5.68
Genetic influences on impulsivity, risk taking, stress responsivity and vulnerability to drug abuse and addiction. Nat Neurosci (2005) 4.83
Toll-like receptor 3 and geographic atrophy in age-related macular degeneration. N Engl J Med (2008) 4.46
Cocaine vaccine for the treatment of cocaine dependence in methadone-maintained patients: a randomized, double-blind, placebo-controlled efficacy trial. Arch Gen Psychiatry (2009) 3.61
CFH and LOC387715/ARMS2 genotypes and treatment with antioxidants and zinc for age-related macular degeneration. Ophthalmology (2008) 2.90
Pharmacogenetics and human molecular genetics of opiate and cocaine addictions and their treatments. Pharmacol Rev (2005) 2.23
Vaccine pharmacotherapy for the treatment of cocaine dependence. Biol Psychiatry (2005) 2.18
Effects of smoking abstinence on visuospatial working memory function in schizophrenia. Neuropsychopharmacology (2002) 2.08
A placebo controlled trial of bupropion for smoking cessation in schizophrenia. Biol Psychiatry (2002) 1.86
Neural activity associated with stress-induced cocaine craving: a functional magnetic resonance imaging study. Psychopharmacology (Berl) (2005) 1.84
Methadone versus buprenorphine with contingency management or performance feedback for cocaine and opioid dependence. Am J Psychiatry (2005) 1.82
The single nucleotide polymorphism A118G alters functional properties of the human mu opioid receptor. J Neurochem (2007) 1.78
Risk assessment model for development of advanced age-related macular degeneration. Arch Ophthalmol (2011) 1.75
Substance abuse vaccines. Ann N Y Acad Sci (2008) 1.74
Consensus statement on office-based treatment of opioid dependence using buprenorphine. J Subst Abuse Treat (2004) 1.70
Six-month trial of bupropion with contingency management for cocaine dependence in a methadone-maintained population. Arch Gen Psychiatry (2006) 1.66
Prescription pain medication dependence. Am J Psychiatry (2011) 1.65
Treatment outcome predictors for cocaine dependence. Am J Drug Alcohol Abuse (2007) 1.54
Opioid dependence treatment: options in pharmacotherapy. Expert Opin Pharmacother (2009) 1.45
Effects of lofexidine on stress-induced and cue-induced opioid craving and opioid abstinence rates: preliminary findings. Psychopharmacology (Berl) (2006) 1.44
Genes associated with addiction: alcoholism, opiate, and cocaine addiction. Neuromolecular Med (2004) 1.42
Amino acid variant in the kinase binding domain of dual-specific A kinase-anchoring protein 2: a disease susceptibility polymorphism. Proc Natl Acad Sci U S A (2003) 1.33
Challenges in increasing access to buprenorphine treatment for opiate addiction. Am J Addict (2004) 1.29
Choosing a behavioral therapy platform for pharmacotherapy of substance users. Drug Alcohol Depend (2004) 1.28
Therapeutic vaccines for substance dependence. Expert Rev Vaccines (2004) 1.27
Pharmacogenetic randomized trial for cocaine abuse: disulfiram and dopamine β-hydroxylase. Biol Psychiatry (2012) 1.27
Effects of progesterone treatment on cocaine responses in male and female cocaine users. Pharmacol Biochem Behav (2004) 1.26
Sex differences in brain activation during stress imagery in abstinent cocaine users: a functional magnetic resonance imaging study. Biol Psychiatry (2005) 1.26
Prediction of treatment outcome by baseline urine cocaine results and self-reported cocaine use for cocaine and opioid dependence. Am J Drug Alcohol Abuse (2003) 1.23
Vaccines for cocaine abuse. Hum Vaccin (2009) 1.23
Performance of cocaine dependent individuals and controls on a response inhibition task with varying levels of difficulty. Am J Drug Alcohol Abuse (2007) 1.21
Emerging pharmacological strategies in the fight against cocaine addiction. Expert Opin Emerg Drugs (2006) 1.20
Progression of geographic atrophy and genotype in age-related macular degeneration. Ophthalmology (2010) 1.18
Novel approaches to the treatment of cocaine addiction. CNS Drugs (2005) 1.18
Yohimbine-induced withdrawal and anxiety symptoms in opioid-dependent patients. Biol Psychiatry (2002) 1.16
Search for genetic markers and functional variants involved in the development of opiate and cocaine addiction and treatment. Ann N Y Acad Sci (2010) 1.16
Redefinition of the human kappa opioid receptor gene (OPRK1) structure and association of haplotypes with opiate addiction. Pharmacogenetics (2004) 1.16
Consistent effects of genes involved in reverse cholesterol transport on plasma lipid and apolipoprotein levels in CARDIA participants. Arterioscler Thromb Vasc Biol (2006) 1.14
Treatment of patients with substance use disorders, second edition. American Psychiatric Association. Am J Psychiatry (2007) 1.14
Perfusion abnormalities and decision making in cocaine dependence. Biol Psychiatry (2004) 1.11
The future of vaccines in the management of addictive disorders. Curr Psychiatry Rep (2007) 1.11
Novel pharmacotherapeutic treatments for cocaine addiction. BMC Med (2011) 1.10
Traditional medicine in the treatment of drug addiction. Am J Drug Alcohol Abuse (2009) 1.09
Combating opiate dependence: a comparison among the available pharmacological options. Expert Opin Pharmacother (2004) 1.09
Combined cocaine hydrolase gene transfer and anti-cocaine vaccine synergistically block cocaine-induced locomotion. PLoS One (2012) 1.08
Randomized, double blind, placebo-controlled trial of disulfiram for the treatment of cocaine dependence in methadone-stabilized patients. Drug Alcohol Depend (2010) 1.08
Free radicals, antioxidant defense systems, and schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry (2013) 1.08
A multidisciplinary Care Coordination Team improves emergency department discharge planning practice. Med J Aust (2002) 1.07
A functional haplotype implicated in vulnerability to develop cocaine dependence is associated with reduced PDYN expression in human brain. Neuropsychopharmacology (2008) 1.07
Anti-cocaine vaccine development. Expert Rev Vaccines (2010) 1.03
Pharmacogenetic treatments for drug addiction: cocaine, amphetamine and methamphetamine. Am J Drug Alcohol Abuse (2009) 1.02
Decreased levels of serum brain-derived neurotrophic factor in drug-naïve first-episode schizophrenia: relationship to clinical phenotypes. Psychopharmacology (Berl) (2009) 1.02
A preliminary placebo-controlled trial of selegiline hydrochloride for smoking cessation. Biol Psychiatry (2003) 1.02
A vaccine against methamphetamine attenuates its behavioral effects in mice. Drug Alcohol Depend (2012) 1.01
Tiagabine increases cocaine-free urines in cocaine-dependent methadone-treated patients: results of a randomized pilot study. Addiction (2003) 1.00
Noradrenergic α₁ receptor antagonist treatment attenuates positive subjective effects of cocaine in humans: a randomized trial. PLoS One (2012) 0.99
Low BDNF is associated with cognitive impairment in chronic patients with schizophrenia. Psychopharmacology (Berl) (2012) 0.98
Cigarette smoking in male patients with chronic schizophrenia in a Chinese population: prevalence and relationship to clinical phenotypes. PLoS One (2012) 0.98
Pharmacogenetic treatments for drug addiction: alcohol and opiates. Am J Drug Alcohol Abuse (2008) 0.98
The Alcohol Clinical Trials Initiative (ACTIVE): purpose and goals for assessing important and salient issues for medications development in alcohol use disorders. Neuropsychopharmacology (2011) 0.96
BDNF levels and genotype are associated with antipsychotic-induced weight gain in patients with chronic schizophrenia. Neuropsychopharmacology (2007) 0.96
Efficacy of opiate maintenance therapy and adjunctive interventions for opioid dependence with comorbid cocaine use disorders: A systematic review and meta-analysis of controlled clinical trials. Am J Drug Alcohol Abuse (2009) 0.96
Decreased serum BDNF levels in chronic institutionalized schizophrenia on long-term treatment with typical and atypical antipsychotics. Prog Neuropsychopharmacol Biol Psychiatry (2009) 0.95
Anti-cocaine antibody and butyrylcholinesterase-derived cocaine hydrolase exert cooperative effects on cocaine pharmacokinetics and cocaine-induced locomotor activity in mice. Chem Biol Interact (2012) 0.95
Short-term tropisetron treatment and cognitive and P50 auditory gating deficits in schizophrenia. Am J Psychiatry (2012) 0.95
Association of functional catechol O-methyl transferase (COMT) Val108Met polymorphism with smoking severity and age of smoking initiation in Chinese male smokers. Psychopharmacology (Berl) (2007) 0.95
Serum BDNF levels and weight gain in schizophrenic patients on long-term treatment with antipsychotics. J Psychiatr Res (2006) 0.94
A morphine conjugate vaccine attenuates the behavioral effects of morphine in rats. Prog Neuropsychopharmacol Biol Psychiatry (2013) 0.94
Effects of anti-cocaine vaccine and viral gene transfer of cocaine hydrolase in mice on cocaine toxicity including motor strength and liver damage. Chem Biol Interact (2012) 0.94
Disulfiram facilitates the development and expression of locomotor sensitization to cocaine in rats. Biol Psychiatry (2003) 0.93
Treatment of patients with substance use disorders, second edition. American Psychiatic Association. Am J Psychiatry (2006) 0.93
Gender differences in cognitive function of patients with chronic schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry (2012) 0.93
Clinical efficacy of gabapentin versus tiagabine for reducing cocaine use among cocaine dependent methadone-treated patients. Drug Alcohol Depend (2006) 0.92
Litter gender composition and sex affect maternal behavior and DNA methylation levels of the oprm1 gene in rat offspring. Front Psychiatry (2011) 0.92
Genetics of dopamine and its contribution to cocaine addiction. Behav Genet (2006) 0.92
The impact of disulfiram treatment on the reinforcing effects of cocaine: a randomized clinical trial. PLoS One (2012) 0.92
Effect of rapamycin on cue-induced drug craving in abstinent heroin addicts. Eur J Pharmacol (2009) 0.91
Sex and litter effects on anxiety and DNA methylation levels of stress and neurotrophin genes in adolescent rats. Dev Psychobiol (2013) 0.91
Epigenetics of drug abuse: predisposition or response. Pharmacogenomics (2012) 0.91
Cerebral perfusion defects in combined cocaine and alcohol dependence. Drug Alcohol Depend (2002) 0.91
Comorbid major depressive disorder as a prognostic factor in cocaine-abusing buprenorphine-maintained patients treated with desipramine and contingency management. Am J Drug Alcohol Abuse (2003) 0.89
Prevalence, demographic and clinical correlates of suicide attempts in Chinese medicated chronic inpatients with schizophrenia. J Psychiatr Res (2013) 0.89
Sertraline delays relapse in recently abstinent cocaine-dependent patients with depressive symptoms. Addiction (2011) 0.89
Improving PTSD/substance abuse treatment in the VA: a survey of providers. Am J Addict (2010) 0.89
Tissue-specific DNA methylation of the human prodynorphin gene in post-mortem brain tissues and PBMCs. Pharmacogenet Genomics (2011) 0.89
Pharmacotherapeutics for substance-use disorders: a focus on dopaminergic medications. Expert Opin Investig Drugs (2013) 0.89
Cognitive and serum BDNF correlates of BDNF Val66Met gene polymorphism in patients with schizophrenia and normal controls. Hum Genet (2012) 0.89
Disrupted antioxidant enzyme activity and elevated lipid peroxidation products in schizophrenic patients with tardive dyskinesia. J Clin Psychiatry (2007) 0.89
Progesterone effects on cocaine use in male cocaine users maintained on methadone: a randomized, double-blind, pilot study. Exp Clin Psychopharmacol (2007) 0.88
Efficacy of dose and contingency management procedures in LAAM-maintained cocaine-dependent patients. Drug Alcohol Depend (2005) 0.88
Prospective randomized controlled trial of combination ranibizumab (Lucentis) and bromfenac (Xibrom) for neovascular age-related macular degeneration: a pilot study. Retina (2012) 0.87
Contribution of regulatory and structural variations in APOE to predicting dyslipidemia. J Lipid Res (2005) 0.87
Time-dependent neuroendocrine alterations and drug craving during the first month of abstinence in heroin addicts. Am J Drug Alcohol Abuse (2009) 0.87
Spontaneous development of IgM anti-cocaine antibodies in habitual cocaine users: effect on IgG antibody responses to a cocaine cholera toxin B conjugate vaccine. Am J Addict (2013) 0.86
The novel oxidative stress marker thioredoxin is increased in first-episode schizophrenic patients. Schizophr Res (2009) 0.86
Utility of crossover designs in clinical trials: efficacy of desipramine vs. placebo in opioid-dependent cocaine abusers. Am J Addict (2002) 0.86
Catechol-O-methyltransferase (COMT) gene variants: possible association of the Val158Met variant with opiate addiction in Hispanic women. Am J Med Genet B Neuropsychiatr Genet (2008) 0.86